Pharma BD Deal Intelligence
Bargain so far: Hengrui handed its GLP-1 trio to Hercules CM NewCo for $110M upfront and 19.9% equity, and that NewCo, Kailera Therapeutics, priced a $625M Nasdaq IPO at $16/share in April 2026 — though Hengrui's real payoff still rides on up to $5.725B in unearned sales milestones.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →China's Jiangsu Hengrui Pharmaceuticals said on Thursday it would grant exclusive rights outside greater China for its GLP-1 drug portfolio to a newly formed…
Hengrui's $6 billion-plus GLP-1 out-licensing to Hercules CM NewCo represents the clearest signal yet that Chinese pharmas can command western-scale economics…
Kailera (KLRA) raised $625M in its Nasdaq IPO at $16/share (Apr 17, 2026), a record-setting biotech debut, to fund its Hengrui-derived obesity pipeline.
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
In May 2024, Jiangsu Hengrui Pharmaceuticals granted exclusive ex-Greater China rights to develop, manufacture and commercialize its GLP-1 portfolio (HRS-7535, HRS9531, HRS-4729) to Hercules CM NewCo, a Delaware company backed by Bain Capital, Atlas Venture and RTW Investments. Hengrui received $110M upfront/near-term, up to $200M in development and regulatory milestones, up to $5.725B in sales milestones, tiered royalties, and a 19.9% equity stake. The NewCo launched publicly as Kailera Therapeutics (CEO Ron Renaud) and rapidly capitalized the platform: a $400M Series A (Oct 2024) and a $600M Series B (Oct 2025), followed by a record-setting $625M Nasdaq IPO (KLRA) on April 17, 2026 priced at $16/share. The deal thesis has been strongly validated: lead asset HRS9531 — an injectable dual GLP-1/GIP receptor agonist developed globally by Kailera as ribupatide (KAI-9531) — reported positive Phase 3 topline data in China (July 15, 2025), with up to 19.2% mean weight loss at 48 weeks, and Hengrui has filed for Chinese approval. Kailera began its global KaiNETIC Phase 3 program (three trials, doses up to 10 mg over 76 weeks; data expected ~2028) with first participants randomized in January 2026, and reported positive Phase 2 data for oral ribupatide in February 2026.
109M US cases/yr · $150.0B Global obesity + T2D GLP-1 class peak-year analyst consensus (2030) · 6035 Total Hengrui-Hercules deal size (USD MM upfront + milestones)
Obesity affects approximately 41.9% of US adults (CDC NHANES 2017-March 2020), roughly 109 million people, and is a leading driver of type 2 diabetes, cardiovascular disease, NAFLD/MASH, obstructive sleep apnea and chronic kidney disease. Type 2 diabetes affects an additional 37.3 million Americans (CDC National Diabetes Statistics Report 2022), with 96 million adults classified as prediabetic. The incretin class (GLP-1 receptor agonists and GLP-1/GIP dual agonists) has redefined both indications since 2021, moving from glucose control to weight loss (15-22% placebo-adjusted) and cardiovascular/renal outcome benefit (SELECT, FLOW). Supply of semaglutide and tirzepatide remains constrained, insurance coverage is inconsistent (Medicare cannot cover pure weight-loss indications under statute, though CMS permits coverage when the same molecule has a cardiovascular indication), and adherence at 12 months is <35%. Oral small-molecule and next-generation combination incretins are the most strategically contested category in pharma, with peak-year analyst consensus for the class now exceeding $150B by 2030. Chinese GLP-1 innovator molecules have moved rapidly into global competition via ex-China NewCo licensing structures, of which Hengrui/Hercules is the archetype.
The GLP-1/incretin obesity and diabetes landscape is the most capital-intensive race in pharma. Injectable GLP-1 monotherapy: Ozempic / Wegovy (semaglutide, Novo Nordisk) set the category, with CV and renal outcome benefit; $15B+ 2024 sales. Dual GLP-1/GIP: Mounjaro / Zepbound (tirzepatide, Eli Lilly) leads on weight loss magnitude (22.5% in SURMOUNT-1); $16B 2024 sales across diabetes and obesity. Oral small molecules: orforglipron (Lilly oral GLP-1, Phase 3 ACHIEVE/ATTAIN readouts 2025), Rybelsus (oral semaglutide, Novo, approved but low bioavailability), and HRS-7535 (Hengrui/Hercules oral GLP-1). Injectable next-gen: HRS-9531 (GLP-1/GIP dual, Hercules, Phase 3 in China), retatrutide (Lilly GLP-1/GIP/glucagon triple, Phase 3, 24% weight loss), CagriSema (Novo, amylin + semaglutide combo), survodutide (Boehringer/Zealand). Amylin-based: amycretin (Novo oral + subq). The Hengrui portfolio gives Kailera a full-spectrum GLP-1 franchise (injectable dual, injectable GLP-1, oral) at a fraction of the capital required to discover in-house, targeting the 2028-2031 window when first-mover supply constraints ease and share shifts on differentiation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hercules CM NewCo Inc. (Kailera Therapeutics) / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (this deal) | 2024 | $6.0B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
| AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance | 2012 | $3.5B | 77 |
| Roche Holding AG / Carmot Therapeutics Inc. | 2023 | $2.7B | 72 |
← Browse all deals · How we score deals
More: 2024 deals · Metabolic deals